Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Neurodegenerative Disease Management
|
March 9, 2018
Octagam<sup>®</sup> for chronic inflammatory demyelinating polyneuropathy: results from three observational studies
Stefan Wietek
Hematology (Amsterdam, Netherlands)
|
October 13, 2017
Tolerability and safety of the intravenous immunoglobulin octagam<sup>®</sup> 10% in patients with immune thrombocytopenia: a post-authorisation safety analysis of two non-interventional phase IV trials
Stefan Wietek, Daniel Svorc, Anette Debes, et al.
International Journal of Clinical Pharmacology and Therapeutics
|
October 11, 2016
Tolerability and safety of Octagam® (IVIG): a post-authorization safety analysis of four non-interventional phase IV trials
Wolfgang Frenzel, Stefan Wietek, Tor-Einar Svae, et al.
Journal of Clinical Movement Disorders
|
September 5, 2020
AbobotulinumtoxinA using 2-mL dilution (500 U/2-mL) maintains durable improvement across multiple treatment cycles
Khashayar Dashtipour, Stefan Wietek, Bruce Rubin, et al.
FEBS Letters
|
January 22, 2002
Non-antisense cellular responses to oligonucleotides
Alain Anselmet, Ebrahim Mayat, Stefan Wietek, et al.
Plos One
|
April 14, 2021
Correction: Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study
Atul T Patel, Mark F Lew, Khashayar Dashtipour, et al.
Plos One
|
February 1, 2021
Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study
Atul T Patel, Mark F Lew, Khashayar Dashtipour, et al.
Journal of Neuroimmunology
|
December 3, 2014
Predicting therapeutic efficacy of intravenous immunoglobulin (IVIG) in individual patients with relapsing remitting multiple sclerosis (RRMS) by functional genomics
Thomas Berger, Christian Jacobi, Judith Haas, et al.
Clinical Parkinsonism & Related Disorders
|
December 10, 2021
AbobotulinumtoxinA provides flexibility for the treatment of cervical dystonia with 500 U/1 mL and 500 U/2 mL dilutions
Mark F Lew, Robert A Hauser, Stuart H Isaacson, et al.
The Lancet. Neurology
|
February 5, 2013
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial
Richard Dodel, Axel Rominger, Peter Bartenstein, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Neurodegenerative Disease Management
|
March 9, 2018
Octagam<sup>®</sup> for chronic inflammatory demyelinating polyneuropathy: results from three observational studies
Stefan Wietek
Hematology (Amsterdam, Netherlands)
|
October 13, 2017
Tolerability and safety of the intravenous immunoglobulin octagam<sup>®</sup> 10% in patients with immune thrombocytopenia: a post-authorisation safety analysis of two non-interventional phase IV trials
Stefan Wietek, Daniel Svorc, Anette Debes, et al.
International Journal of Clinical Pharmacology and Therapeutics
|
October 11, 2016
Tolerability and safety of Octagam® (IVIG): a post-authorization safety analysis of four non-interventional phase IV trials
Wolfgang Frenzel, Stefan Wietek, Tor-Einar Svae, et al.
Journal of Clinical Movement Disorders
|
September 5, 2020
AbobotulinumtoxinA using 2-mL dilution (500 U/2-mL) maintains durable improvement across multiple treatment cycles
Khashayar Dashtipour, Stefan Wietek, Bruce Rubin, et al.
FEBS Letters
|
January 22, 2002
Non-antisense cellular responses to oligonucleotides
Alain Anselmet, Ebrahim Mayat, Stefan Wietek, et al.
Plos One
|
April 14, 2021
Correction: Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study
Atul T Patel, Mark F Lew, Khashayar Dashtipour, et al.
Plos One
|
February 1, 2021
Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study
Atul T Patel, Mark F Lew, Khashayar Dashtipour, et al.
Journal of Neuroimmunology
|
December 3, 2014
Predicting therapeutic efficacy of intravenous immunoglobulin (IVIG) in individual patients with relapsing remitting multiple sclerosis (RRMS) by functional genomics
Thomas Berger, Christian Jacobi, Judith Haas, et al.
Clinical Parkinsonism & Related Disorders
|
December 10, 2021
AbobotulinumtoxinA provides flexibility for the treatment of cervical dystonia with 500 U/1 mL and 500 U/2 mL dilutions
Mark F Lew, Robert A Hauser, Stuart H Isaacson, et al.
The Lancet. Neurology
|
February 5, 2013
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial
Richard Dodel, Axel Rominger, Peter Bartenstein, et al.
Page
of 1